Clearline Capital LP Purchases 284,921 Shares of The Cooper Companies, Inc. $COO

Clearline Capital LP raised its position in The Cooper Companies, Inc. (NASDAQ:COO) by 299.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 380,090 shares of the medical device company’s stock after acquiring an additional 284,921 shares during the quarter. Cooper Companies makes up 1.2% of Clearline Capital LP’s investment portfolio, making the stock its 11th largest position. Clearline Capital LP owned 0.19% of Cooper Companies worth $26,059,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of COO. Mesirow Financial Investment Management Inc. grew its position in shares of Cooper Companies by 1.3% in the 3rd quarter. Mesirow Financial Investment Management Inc. now owns 14,017 shares of the medical device company’s stock worth $961,000 after buying an additional 175 shares during the last quarter. Pacer Advisors Inc. lifted its position in shares of Cooper Companies by 0.8% in the 3rd quarter. Pacer Advisors Inc. now owns 23,079 shares of the medical device company’s stock worth $1,582,000 after purchasing an additional 182 shares during the period. Citizens Financial Group Inc. RI boosted its stake in shares of Cooper Companies by 2.7% during the 3rd quarter. Citizens Financial Group Inc. RI now owns 7,181 shares of the medical device company’s stock valued at $492,000 after purchasing an additional 192 shares in the last quarter. Close Asset Management Ltd increased its position in shares of Cooper Companies by 7.2% during the third quarter. Close Asset Management Ltd now owns 3,319 shares of the medical device company’s stock valued at $227,000 after buying an additional 224 shares during the period. Finally, ProShare Advisors LLC raised its stake in Cooper Companies by 0.7% in the third quarter. ProShare Advisors LLC now owns 35,874 shares of the medical device company’s stock worth $2,460,000 after buying an additional 239 shares in the last quarter. 24.39% of the stock is owned by institutional investors.

Insider Transactions at Cooper Companies

In other news, Director Cynthia L. Lucchese purchased 1,784 shares of the company’s stock in a transaction that occurred on Monday, December 22nd. The shares were bought at an average price of $84.06 per share, for a total transaction of $149,963.04. Following the purchase, the director directly owned 9,445 shares in the company, valued at approximately $793,946.70. This trade represents a 23.29% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Albert G. White III acquired 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 16th. The shares were purchased at an average cost of $80.80 per share, for a total transaction of $808,000.00. Following the completion of the transaction, the chief executive officer directly owned 236,151 shares in the company, valued at $19,081,000.80. The trade was a 4.42% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders bought 16,014 shares of company stock valued at $1,304,416. 2.08% of the stock is currently owned by corporate insiders.

Cooper Companies Price Performance

COO stock opened at $69.92 on Friday. The company has a debt-to-equity ratio of 0.22, a quick ratio of 0.79 and a current ratio of 1.34. The firm has a 50 day moving average price of $81.23 and a 200-day moving average price of $75.96. The Cooper Companies, Inc. has a 52-week low of $61.78 and a 52-week high of $89.83. The firm has a market capitalization of $13.64 billion, a price-to-earnings ratio of 34.61, a PEG ratio of 1.80 and a beta of 1.02.

Cooper Companies (NASDAQ:COO) last posted its quarterly earnings results on Thursday, March 5th. The medical device company reported $1.10 earnings per share for the quarter, topping the consensus estimate of $1.03 by $0.07. The company had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.02 billion. Cooper Companies had a return on equity of 10.34% and a net margin of 9.67%.The firm’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.92 EPS. Cooper Companies has set its Q2 2026 guidance at 4.580-4.660 EPS. Equities research analysts forecast that The Cooper Companies, Inc. will post 3.98 EPS for the current fiscal year.

Wall Street Analyst Weigh In

COO has been the subject of several research analyst reports. Citigroup lowered their price objective on shares of Cooper Companies from $88.00 to $87.00 and set a “neutral” rating for the company in a report on Friday, March 6th. The Goldman Sachs Group restated a “sell” rating and issued a $73.00 target price on shares of Cooper Companies in a research note on Friday, January 9th. Barclays lifted their price target on Cooper Companies from $98.00 to $103.00 and gave the company an “overweight” rating in a research report on Friday, March 6th. Wells Fargo & Company increased their price objective on Cooper Companies from $72.00 to $82.00 and gave the stock an “equal weight” rating in a report on Friday, December 5th. Finally, Rothschild & Co Redburn lowered Cooper Companies from a “buy” rating to a “neutral” rating and set a $85.00 price objective for the company. in a research report on Wednesday, March 4th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $90.79.

About Cooper Companies

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.